Program
inpegsomatropin
Also written as “Inpegsomatropin Injection” and “Inpegsomatropin-Injection”.
Its studies are mostly in Dwarfism, Pituitary · Turner Syndrome, led by Xiamen Amoytop Biotech.
Furthest: phase 3, since Apr 6, 20255 company-led studies, 5 open or runningNext primary completion: Dec 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Xiamen Amoytop Biotech | 55 open or running | phase 3since Apr 6, 2025 | Apr 6, 2025 | Dec 31, 2027phase 2 · NCT07551804 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 6, 2025First study: phase 3 study in Idiopathic Short StatureFirst studyNCT06927310 · 300 planned · China
- Dec 15, 2025Phase 3 study in Small for Gestational AgeNCT07309562 · 141 planned · China
- Apr 15, 2026Phase 2 study in Dwarfism, PituitaryNCT07551804 · 36 planned · China
- May 21, 2026Phase 3 study in Turner SyndromeNCT07614152 · 84 planned · China
- Oct 9, 2026No phase study in Idiopathic Short StatureNCT07894341 · 300 planned · China
Ahead
- Dec 31, 2027Primary completion: phase 2 study in Dwarfism, PituitaryNCT07551804
- Mar 2028Primary completion: phase 3 study in Small for Gestational AgeNCT07309562
- Mar 30, 2028Primary completion: phase 3 study in Turner SyndromeNCT07614152
- Aug 31, 2041Primary completion: no phase study in Idiopathic Short StatureNCT07894341
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07894341Idiopathic Short Stature · China | – | Recruiting | Aug 31, 2041 | 300 |
| NCT07614152Turner Syndrome · China | 3 | Recruiting | Mar 30, 2028 | 84 |
| NCT07551804Dwarfism, Pituitary · China | 2 | Recruiting | Dec 31, 2027 | 36 |
| NCT07309562Small for Gestational Age · China | 3 | Recruiting | Mar 2028 | 141 |
| NCT06927310Idiopathic Short Stature · China | 3 | Recruiting | Mar 2026 | 300 |
How it is read
Names in the registry
- “Inpegsomatropin Injection”, 7 entries
- “Inpegsomatropin-Injection”, 1 entry
Conditions, from the studies’ own filings
- Dwarfism, Pituitary, 1 study
- Turner Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.